Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Year: 2025
Type: other
Abstract: Tumor response, OS, and PFS. A and B, A summary of (A) best reduction and (B) percent change from baseline in the sum of the diameters of target tumors in each patient with NSCLC treated with nivolumab. C and D, A summary of (C) best reduction and (D) percent change from baseline in the sum of the diameters of target tumors in each patient with gastric cancer (GC) treated with nivolumab. E and F, A summary of the probability of OS in patients with (E) NSCLC and (F) GC. G and H, A summary of the probability of PFS in patients with (G) NSCLC and (H) GC. The 95% CI was determined by the Brookmeyer–Crowley method with log–log transformation. Circles indicate censoring. CR, complete response; SD, stable disease.
Authors: Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka, Katsunori Shinozaki, Nobuhiko Seki, Hiroki Hara, Yukiya Narita, Takeshi Shiraishi, Yosuke Tamura, Akihito Tsuji, Kunihiro Tsuji, Naohiro Watanabe, Hiroshi Tanaka, Toshifumi Yamaguchi, Kensei Yamaguchi, Hiroki Izumi, Yasunori Ushida, Hideaki Suna
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415114097
Cites:
Cited by:
Related to: